A key concern with the clinical application of IgE immunotherapy is the potential of IgE bound to blood basophils or mast cells to encounter agents in the circulation able to cross-link IgE and stimulate cell degranulation, resulting in type 1 hypersensitivity and systemic anaphylaxis. Here, IGHE is linked to anaphylaxis.